Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.

Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.

Esophageal carcinomas have been shown to express Fas ligand (FasL) and down-regulate Fas to escape from host immune surveillance. Circulating soluble FasL (sFasL) has been suggested to provide protection from Fas-mediated apoptosis. The aim of this study was to assess serum sFasL levels in esophagea...

Full description

Bibliographic Details
Main Authors: Lech Chyczewski, Wieslawa Niklinska, Wojciech Laudanski, Grzegorz Lapuc, Piotr Dziegielewski, Anetta Sulewska, Oksana Kowalczuk, Miroslaw Kozlowski, Jacek Niklinski, Jerzy Laudanski
Format: Article
Language:English
Published: Via Medica 2007-10-01
Series:Folia Histochemica et Cytobiologica
Online Access:http://czasopisma.viamedica.pl/fhc/article/view/4524

Internet

http://czasopisma.viamedica.pl/fhc/article/view/4524

Similar Items